Clinical trial
A Phase Ib Study of Guadecitabine (SGI-110) and Durvalumab (MEDI 4736) in Patients With Advanced Hepatocellular Carcinoma, Pancreatic Adenocarcinoma, and Cholangiocarcinoma/Gallbladder Cancer
NCT03257761 is registered in ClinicalTrials.gov with University of Southern California as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase Ib Study of Guadecitabine (SGI-110) and Durvalumab (MEDI 4736) in Patients With Advanced Hepatocellular Carcinoma, Pancreatic Adenocarcinoma, and Cholangiocarcinoma/Gallbladder Cancer
- Lead sponsor
- University of Southern California
- Phase
- Phase 1
- Overall status
- Active, not recruiting
- Start date
- February 7, 2018
- Completion date
- December 31, 2026
- Enrollment
- 55 (actual)
- Sites
- 3
Conditions
As the registry lists them; a condition with its own page is linked.
extrahepatic bile duct adenocarcinoma, biliary type, gallbladder adenocarcinoma, biliary type, metastatic pancreatic adenocarcinoma, recurrent cholangiocarcinoma, recurrent gallbladder carcinoma, recurrent hepatocellular carcinoma, recurrent intrahepatic cholangiocarcinoma, recurrent pancreatic carcinoma, stage iii gallbladder cancer ajcc v7, stage iii hepatocellular carcinoma ajcc v7, stage iii intrahepatic cholangiocarcinoma ajcc v7, stage iii pancreatic cancer ajcc v6 and v7, stage iiia gallbladder cancer ajcc v7, stage iiia hepatocellular carcinoma ajcc v7, stage iiib gallbladder cancer ajcc v7, stage iiib hepatocellular carcinoma ajcc v7, stage iiic hepatocellular carcinoma ajcc v7, stage iv gallbladder cancer ajcc v7, stage iv hepatocellular carcinoma ajcc v7, stage iv pancreatic cancer ajcc v6 and v7, stage iva gallbladder cancer ajcc v7, stage iva hepatocellular carcinoma ajcc v7, stage iva intrahepatic cholangiocarcinoma ajcc v7, stage ivb gallbladder cancer ajcc v7, stage ivb hepatocellular carcinoma ajcc v7, stage ivb intrahepatic cholangiocarcinoma ajcc v7, unresectable gallbladder carcinoma, unresectable pancreatic carcinoma